Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer

Inclusion Criteria:

* IIA-IIIC phase esophageal squamous cell carcinoma confirmed by histopathology and immunohistochemistry.
* R0 resection has been performed at least before 4 weeks.
* ECOG PS score: 0-1 points.
* Estimated survival time: at least 12 weeks.
* No radiotherapy, chemotherapy or molecular targeted therapy before.
* Main organs are functional, which meet the following criteria:

Blood Routine:

HB≥90 g/L（No blood transfusion within 14 days）, ANC≥1.5×109/L, PLT ≥80×109/L. Biochemical examination： ALB≥30g / L（No blood transfusion within 14 days）, ALT\<2ULN； AST\<2ULN TBIL≤1.5ULN； Plasma Cr≤1.5ULN；

* Volunteer with signed informed consent form, good compliance and good follow-up cooperation.
* Patients who the investigator believws they can benefit.

Exclusion Criteria:

* Those who have had other malignant tumors in the past or at the same time.
* Pregnant or lactating women.
* Patients with grade-II or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTC interval ≥ 450 ms) and cardiac dysfunction according to NYHA criteria III to IV. Cardiac color Doppler examination: LVEF (left ventricular ejection) Score) \<50%.
* Have clear gastrointestinal bleeding concerns (such as local active ulcer lesions, fecal occult blood ++), and a history of gastrointestinal bleeding within 6 months.
* Have a history of mental illness or psychotropic substance abuse.
* Patients who have participated in other drug clinical trials within 4 weeks.
* According to the investigator's judgment, patients who are at a risk or have accompanying disease.
* Patients who believe that they are unsuitable for inclusion.